Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2023 November 28, 2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia November 16, 2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis November 1, 2023 argenx to Present at Upcoming Investor Conferences November 1, 2023 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions October 31, 2023 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update October 24, 2023 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023 September 21, 2023 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis September 15, 2023 argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis August 30, 2023 argenx to Present at Upcoming Investor Conferences July 27, 2023 argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update July 24, 2023 argenx announces closing of global offering July 20, 2023 argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
